LU83661A1 - Derive d'aminoalcoyl furanne,procede pour sa preparation et composition pharmaceutique comprenant ce derive - Google Patents

Derive d'aminoalcoyl furanne,procede pour sa preparation et composition pharmaceutique comprenant ce derive Download PDF

Info

Publication number
LU83661A1
LU83661A1 LU83661A LU83661A LU83661A1 LU 83661 A1 LU83661 A1 LU 83661A1 LU 83661 A LU83661 A LU 83661A LU 83661 A LU83661 A LU 83661A LU 83661 A1 LU83661 A1 LU 83661A1
Authority
LU
Luxembourg
Prior art keywords
ranitidine hydrochloride
ranitidine
hydrochloride
propan
solution
Prior art date
Application number
LU83661A
Other languages
English (en)
French (fr)
Inventor
Derek Leslie Crookes
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU83661(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of LU83661A1 publication Critical patent/LU83661A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
LU83661A 1980-10-01 1981-10-01 Derive d'aminoalcoyl furanne,procede pour sa preparation et composition pharmaceutique comprenant ce derive LU83661A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8031634 1980-10-01
GB8031634 1980-10-01

Publications (1)

Publication Number Publication Date
LU83661A1 true LU83661A1 (fr) 1983-06-08

Family

ID=10516407

Family Applications (1)

Application Number Title Priority Date Filing Date
LU83661A LU83661A1 (fr) 1980-10-01 1981-10-01 Derive d'aminoalcoyl furanne,procede pour sa preparation et composition pharmaceutique comprenant ce derive

Country Status (29)

Country Link
US (2) US4521431A (sk)
JP (1) JPS5791983A (sk)
KR (1) KR870001431B1 (sk)
AT (1) AT389696B (sk)
AU (1) AU549119B2 (sk)
BE (1) BE890574A (sk)
CA (1) CA1202638A (sk)
CH (1) CH652122A5 (sk)
CZ (1) CZ280885B6 (sk)
DE (1) DE3139134A1 (sk)
DK (2) DK167794B1 (sk)
ES (1) ES505951A0 (sk)
FR (1) FR2491067A1 (sk)
GR (1) GR72499B (sk)
HK (1) HK97985A (sk)
IE (1) IE51604B1 (sk)
IL (1) IL63968A (sk)
IT (1) IT1143237B (sk)
KE (1) KE3549A (sk)
LU (1) LU83661A1 (sk)
MY (1) MY8500747A (sk)
NL (1) NL8104482A (sk)
NZ (1) NZ198522A (sk)
PH (2) PH19489A (sk)
PT (1) PT73744B (sk)
SE (1) SE453500B (sk)
SK (1) SK403591A3 (sk)
ZA (1) ZA816809B (sk)
ZW (1) ZW24481A1 (sk)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI88157C (fi) * 1983-07-15 1993-04-13 Richter Gedeon Vegyeszet Foerfarande foer framstaellning av vaetekloriden av 1- 2-/5-dimetylaminometyl-2-(furylmetyltio)-etyl/ -amino-1-metylamino-2-nitroetylen
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
US5338871A (en) * 1991-12-20 1994-08-16 Torcan Chemical Ltd. Preparation of form 1 ranitidine hydrochloride
CN1048984C (zh) * 1991-12-20 2000-02-02 多坎化学有限公司 晶形1呋喃硝胺氢氯化物的制备
SK283674B6 (sk) * 1993-03-12 2003-11-04 Pharmacia & Upjohn Company Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
CA2120874E (en) * 1994-04-08 2002-01-08 Keshava Murthy Form of form 1 ranitidine
US5670671A (en) * 1994-04-08 1997-09-23 Brantford Chemicals Inc. Process for the production of an improved form of form 1 ranitidine
CA2184598C (en) 1994-04-15 2005-05-03 Jeffrey L. Havens Novel crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine
IN181699B (sk) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
NZ272054A (en) * 1994-05-13 1996-05-28 Ranbaxy Lab Ltd Process for producing form 1 ranitidine hydrochloride
IN181698B (sk) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
JPH10500134A (ja) * 1994-05-18 1998-01-06 ヘキスト・マリオン・ルセル・インコーポレイテツド 抗ヒスタミン性ピペリジン誘導体の無水および水和形態、それらの多形態および擬似形態の製造方法
DE69504156T2 (de) 1994-06-24 1998-12-24 Ranbaxy Laboratories, Ltd., New Delhi Verfahren zur Herstellung von Ranitidinhydrochlorid in der Kristallform 1
HUT77946A (hu) * 1994-11-18 1998-12-28 Pharmacia & Upjohn Co. Fluor-kinolon-származék fizikailag stabil, szilárd formája
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
AU1972097A (en) * 1996-03-25 1997-10-17 Hoechst Marion Roussel, Inc. Process for the preparation of form 1 ranitidine hydrochloride
EP0987256B1 (de) 1997-08-08 2001-10-17 Aventis Pharma Deutschland GmbH Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
IT1317858B1 (it) 2000-02-29 2003-07-15 Pharmexcel S R L Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
TW200409746A (en) * 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
EP1562900A4 (en) * 2002-11-08 2006-07-12 Dov Pharmaceutical Inc POLYMORPH OF BICIFADINHYDROCHLORIDE
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US7384557B2 (en) * 2003-07-14 2008-06-10 Applied Ambient Extraction Process Consultants, Llc Method and apparatus for removing solute from a solid solute-bearing product
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
BRPI0613943B1 (pt) 2005-07-27 2021-06-22 Otsuka America Pharmaceutical, Inc Composto, composição farmacêutica o compreendendo, usos de um composto e de uma composição farmacêutica, bem como composição neurobiologicamente ativa
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
CA2756603C (en) * 2006-10-20 2013-05-28 Scinopharm Singapore Pte, Ltd. Process for making crystalline docetaxel trihydrate
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
US9006434B2 (en) 2011-06-30 2015-04-14 Toray Industries, Inc. Crystals of glycine derivative and pharmaceutical use thereof
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN106432148B (zh) * 2015-05-26 2018-04-17 烟台市华文欣欣医药科技有限公司 一种治疗胃病的药物盐酸雷尼替丁化合物的制备方法
CN105030694A (zh) * 2015-08-04 2015-11-11 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂
CN104971053A (zh) * 2015-08-05 2015-10-14 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂
CN105055331A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CH652122A5 (fr) 1985-10-31
CZ403591A3 (en) 1994-01-19
BE890574A (fr) 1982-04-01
JPH0443070B2 (sk) 1992-07-15
DK436281A (da) 1982-04-02
IL63968A (en) 1985-10-31
ES8301954A1 (es) 1983-01-01
JPS5791983A (en) 1982-06-08
SE8105812L (sv) 1982-04-02
GR72499B (sk) 1983-11-15
ES505951A0 (es) 1983-01-01
CA1202638A (en) 1986-04-01
NZ198522A (en) 1985-07-12
DK33792D0 (da) 1992-03-12
ZW24481A1 (en) 1983-04-27
IL63968A0 (en) 1981-12-31
IE51604B1 (en) 1987-01-21
IT8149407A0 (it) 1981-10-01
KE3549A (en) 1985-08-16
ZA816809B (en) 1983-05-25
IT1143237B (it) 1986-10-22
AU7595581A (en) 1982-04-08
FR2491067A1 (fr) 1982-04-02
PH21761A (en) 1988-02-18
KR830007070A (ko) 1983-10-14
DK167923B1 (da) 1994-01-03
DK167794B1 (da) 1993-12-13
KR870001431B1 (ko) 1987-08-06
IE812287L (en) 1982-04-01
PT73744A (en) 1981-10-01
CZ280885B6 (cs) 1996-04-17
HK97985A (en) 1985-12-13
ATA422281A (de) 1989-06-15
PT73744B (en) 1983-10-31
SK277922B6 (en) 1995-08-09
AT389696B (de) 1990-01-10
DE3139134A1 (de) 1982-05-19
MY8500747A (en) 1985-12-31
AU549119B2 (en) 1986-01-16
SK403591A3 (en) 1995-08-09
NL8104482A (nl) 1982-05-03
DK33792A (da) 1992-03-12
US4521431A (en) 1985-06-04
US4672133A (en) 1987-06-09
FR2491067B1 (sk) 1984-09-07
PH19489A (en) 1986-05-14
SE453500B (sv) 1988-02-08
DE3139134C2 (sk) 1990-04-19

Similar Documents

Publication Publication Date Title
LU83661A1 (fr) Derive d'aminoalcoyl furanne,procede pour sa preparation et composition pharmaceutique comprenant ce derive
BE1011664A6 (fr) Sel de paroxetine nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant.
EP2343275B1 (fr) Forme cristalline des énantiomères optiques du modafinil.
EP1675836B1 (fr) Derives du 4-phenylthiazole et leur utilisation comme medicaments pour le traitement de maladies neurodegeneratives, la douleur et l'epilepsie
FR2818977A1 (fr) Procede de preparation du citalopram pur
CH631455A5 (fr) Nouveaux isomeres dextrogyres de spiro-hydantoines asymetriques et compositions pharmaceutiques les contenant.
CH637927A5 (fr) Derives de 4-amino-5-alkylsulfonyl ortho-anisamides et leurs procedes de preparation.
WO2004031160A2 (fr) Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
EP0302980B1 (fr) 1,4-Dihydropyridines, leur procédé de préparation et leur application comme médicaments
NZ242191A (en) Crystalline tiagabine hydrochloride monohydrate, preparation and pharmaceutical compositions thereof
CH618436A5 (sk)
CH635832A5 (fr) Derives du tetrazole et composition pharmaceutique les contenant.
EP1102747B1 (fr) Formes cristallines du osanetant
FR2496104A1 (fr) Nouveaux produits de la serie de la 3-(piperidin-4-yl) 2h-indol-2-one, et procede pour leur preparation
US5663381A (en) Process for preparing form 1 ranitidine hydrochloride
EP2102202B1 (fr) Conglomerats de sels de potassium du tenatoprazole
EP1070083B1 (fr) Formes cristallines du 1s-[1alpha(2s*,3r*),9alpha]-6,10-dioxo-n- (2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9-[[(1-isoquinolyl)carbonyl]- amino]octahydro-6h-piridazino[1,2-a][1,2]diazepine-1-carboxamide
CH646146A5 (fr) Derive du 1alpha,25-dihydroxy cholecalciferol et son procede de preparation.
EP0626372A1 (fr) 2-Hydroxy-3-(1-(1H-imidazol-4-yl)alkyl)-benzènecarboximidamides pour le traitement du glaucome
WO1998024433A1 (fr) Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens
LU81832A1 (fr) Nouveaux derives d'acyl-1h-1,2,4-triazoles et leur procede de preparation
EP1348703A1 (fr) Formes polymorphes du fasidotril, leurs procédés de préparation et compositions pharmaceutiques les contenant
EP0066934A1 (fr) Sels de nitrofurantoine, leur préparation et leur utilisation
BE884946A (fr) Acide aminobenzoique ou son derive comme infredient actif d'une composition pharmaceutique et composition pharmaceutique contenant un tel ingredient actif
CH527840A (fr) Procédé pour préparer des dioxydes de benzothiazine